Entelos Joins Consortium Funded by Pfizer

Entelos Inc.

ENTELOS, Inc.

("Entelos" or "the Company")

Entelos Joins Consortium funded by Pfizer to Identify New Targets for Diabetes
and Obesity

Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, announced today that it has entered an agreement with Pfizer,
Inc. ("Pfizer") and four universities to apply novel computational approaches to
identify new drug targets relevant to diabetes and obesity. Pfizer's initial
funding for the consortium is $14.4 million over the next three years, with an
option to extend for an additional two years.

The consortium, called the Insulin Resistance Pathways Project (IRP Project), is
comprised of top researchers from the University of California, Santa Barbara
(UCSB), the California Institute of Technology (Caltech), the Massachusetts
Institute of Technology (MIT), the University of Massachusetts (UMass), Entelos,
and several research groups from within Pfizer. Please refer to Pfizer's press
release issued on 25 April 2008 for further detail.

The objectives of the consortium include three main activities: i) to collect
targeted dynamic data about insulin pathways within specific human cell types;
ii) to use mathematical models to better understand the biological mechanisms of
these pathways; and, iii) to translate findings to predict human clinical
response using Entelos' computer model of whole-body metabolism. The goal of the
IRP Project is identify drug targets within cells which will ultimately lead to
a compelling new class of diabetes drugs--drugs that will relieve insulin
resistance, a major factor in diabetes and obesity.

"This will be a highly interactive effort," said Preston Hensley, Ph.D., Senior
Director, Worldwide Exploratory Science and Technology at Pfizer, and leader of
the IRP project. "Scientists across Pfizer, including researchers from Pfizer's
Groton, Connecticut Research and Development site as well as from its Research
Technology Center in Cambridge, Mass, will work directly with the external
research teams to progress the research. In addition, we will protect our
academic colleague's fundamental interests by allowing them to publish and/or
patent any discoveries made in the areas of basic biology. We are very fortunate
to be involved with this prestigious team and look forward to advancing new
treatments for these conditions to the clinic, and ultimately, to patients
around the world."

"We are extremely pleased to join this world-class systems biology consortium
driven by Pfizer," added James Karis, president and CEO of Entelos. "We believe
that our PhysioLab platforms and metabolic disease knowledge will help to
identify pathways at the level of the cell that have the greatest impact in
patients. We look forward to making a significant contribution to this
consortium and to helping deliver a prioritized list of new drug targets to
relieve insulin resistance."

For further information please contact:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations Tel: +1 650 572 5400

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson Tel +44 (0) 20 7466 5000

Notes for Editors

Further Details About the IRP Project

The overriding goal of the IRP Project is to build a much better understanding
of insulin signal transduction--or the detailed biochemical effects that insulin
has on the functions within cells--that will lead to novel drug targets for
treating diabetes and obesity.

The general approach will include three main activities: i) generating and
collecting primary time-course biological data from human adipocyte cells (e.g.,
by applying phosphoproteomics (mass spectrometry), gene expression, chemical
genetics, and transcription factor binding methods); ii) using these data to
construct mathematical models and conduct sensitivity analyses to identify
targets that can restore insulin sensitivity; and iii) determining which
pathways have the greatest impact on whole body glucose control using the
Entelos Adipocyte and Metabolism PhysioLab(R) platforms.

The lead researchers of the consortium include Dr. Frank Doyle of UCSB, Dr. John
Doyle of Caltech, Drs. Douglas Lauffenburger, Forest White, and Ernest Fraenkel
of MIT, Dr. Norman Kennedy of UMass, scientists from the Metabolism team at
Entelos, and several groups from within Pfizer including Computational and
Systems Biology, CVMED Exploratory Biology, Drug Safety, and Clinical Research.
Individual labs or research groups will coordinate efforts and be responsible
for specific parts of the data generation, mathematical modeling or analysis, or
translation to whole-body effects over the period of the consortium.

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines and
health-care related consumer products are discovered, developed, and utilized.
The Company leverages its proprietary in silico disease models, "virtual
populations", and toxicology reference systems to develop safer and more
effective drugs for pharmaceutical R&D and to help improve the quality of
health-care related consumer products. Entelos provides customized technology
and research services to global pharmaceutical, health-care, and consumer
products companies in arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization,
and personal care products. The Company is also developing a model in oncology
and is collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.

Entelos Regs (LSE:ENTL)
過去株価チャート
から 5 2024 まで 6 2024